Elutia Overview

  • Year Founded
  • 2015

Year Founded

  • Status
  • Public

  • Employees
  • 26

Employees

  • Stock Symbol
  • ELUT

Stock Symbol

  • Investments
  • 1

  • Share Price
  • $0.82
  • (As of Friday Closing)

Elutia General Information

Description

Elutia Inc develops proprietary drug-eluting biomatrix products for use in surgical reconstruction and related applications. These products are designed to improve the interaction between implanted medical devices and patients. Its products include CanGaroo, designed for implantable electronic devices, and SimpliDerm, used in soft tissue repair, with functions related to implant support and wound management. The company operates in two segments: Women's Health and Cardiovascular. The majority of revenue is derived from the Women's Health segment.

Contact Information

Website
www.elutia.com
Formerly Known As
Aziyo Biologics
Ownership Status
Publicly Held
Financing Status
Formerly PE-Backed
Corporate Office
  • 20 Firstfield Road
  • Gaithersburg, MD 20878
  • United States
+1 (240)
Primary Industry
Therapeutic Devices
Stock Exchange
NAS
Vertical(s)
Corporate Office
  • 20 Firstfield Road
  • Gaithersburg, MD 20878
  • United States
+1 (240)

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Elutia Stock Performance

As of 13-Nov-2026, Elutia’s stock price is $0.82. Its current market cap is $36.4M with 44.4M shares.

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$0.82 $0.87 $0.50 - $1.39 $36.4M 44.4M 184K $1.29

Elutia Financials Summary

As of 30-Sep-2026, Elutia has a trailing 12-month revenue of $13.6M.

In Thousands,
USD
TTM 30-Sep-2026 FY 2025 31-Dec-2025 FY 2024 31-Dec-2024 FY 2023 31-Dec-2023
EV 19,472 53,997 126,653 61,267
Revenue 13,592 12,293 14,467 24,745
EBITDA (26,040) (13,473) (40,987) (31,677)
Net Income 54,391 53,380 (53,949) (37,656)
Total Assets 48,193 62,350 36,127 43,428
Total Debt 12,984 3,942 24,014 23,952
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Elutia Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Elutia‘s full profile, request access.

Request a free trial

Elutia Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Elutia Inc develops proprietary drug-eluting biomatrix products for use in surgical reconstruction and related applicati
Therapeutic Devices
Gaithersburg, MD
26 As of 2025

Audubon, PA
 

Charlotte, NC
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Elutia Competitors (46)

One of Elutia’s 46 competitors is Globus Medical, a Formerly VC-backed company based in Audubon, PA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Globus Medical Formerly VC-backed Audubon, PA
Joerns Healthcare Private Equity-Backed Charlotte, NC
Philips Corporation Amsterdam, Netherlands
Spinal Elements Private Equity-Backed Carlsbad, CA
Spine Wave Venture Capital-Backed Shelton, CT
You’re viewing 5 of 46 competitors. Get the full list »

Elutia Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Elutia Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Elutia‘s full profile, request access.

Request a free trial

Elutia Investments (1)

Elutia’s most recent deal was a Buyout/LBO with Corvivo. The deal was made on 31-May-2017.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Corvivo 31-May-2017 Buyout/LBO Surgical Devices
To view Elutia’s complete investments history, request access »

Elutia ESG

Risk Overview

Risk Rating

Updated November, 04, 2026

37.35 | High Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

Management

Management is related to actions taken to manage ESG issues

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

of 13,585

Rank

Percentile

Pharmaceuticals

Industry

of 852

Rank

Percentile

Biotechnology

Subindustry

of 431

Rank

Percentile

To view Elutia’s complete esg history, request access »

Elutia Affiliates

Subsidiaries (1)

Name Industry Location Year Founded
Corvivo Roswell, GA 2001

Elutia FAQs

  • When was Elutia founded?

    Elutia was founded in 2015.

  • Where is Elutia headquartered?

    Elutia is headquartered in Gaithersburg, MD.

  • What is the size of Elutia?

    Elutia has 26 total employees.

  • What industry is Elutia in?

    Elutia’s primary industry is Therapeutic Devices.

  • Is Elutia a private or public company?

    Elutia is a Public company.

  • What is Elutia’s stock symbol?

    The ticker symbol for Elutia is ELUT.

  • What is the current stock price of Elutia?

    As of 13-Nov-2026 the stock price of Elutia is $0.82.

  • What is the current market cap of Elutia?

    The current market capitalization of Elutia is $36.4M.

  • What is Elutia’s current revenue?

    The trailing twelve month revenue for Elutia is $13.6M.

  • Who are Elutia’s competitors?

    Globus Medical, Joerns Healthcare, Philips, Spinal Elements, and Spine Wave are some of the 46 competitors of Elutia.

  • What is Elutia’s annual earnings per share (EPS)?

    Elutia’s EPS for 12 months was $1.29.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process